Myrelez (Lanreotide Acetate)

Lanreotide acetate, the active ingredient in Myrelez, is a somatostatin analog presented as a long‑acting depot injectable solution for subcutaneous use. It treats acromegaly and gastroenteropancreatic neuroendocrine tumors in adult patients. It is administered as a long‑acting depot injection, allowing sustained hormone control with infrequent dosing. The formulation is approved for use in the European Union.

GNH USA supplies Myrelez as a licensed, GDP‑compliant international pharmaceutical supplier, sourcing the product from EU manufacturers and serving hospitals, oncology centres, and pharmacies worldwide with reliable logistics and regulatory support.

Myrelez (lanreotide acetate) is used in endocrine and neuroendocrine disorders to control excess hormone secretion. - Acromegaly: reduces growth hormone and IGF‑1 levels, improving disease control and related symptoms. - Gastroenteropancreatic neuroendocrine tumors (GEP‑NET): controls tumor‑related hormone secretion and can stabilize disease progression. - Carcinoid syndrome: alleviates flushing and diarrhea caused by hormone‑secreting neuroendocrine tumors.

Common Side Effects: - Injection site pain: mild discomfort at the subcutaneous injection site. - Diarrhea: loose stools occurring shortly after dosing. - Nausea: transient feeling of queasiness. - Hyperglycemia: elevated blood glucose levels, especially in diabetic patients.

Serious or Rare Side Effects: - Gallbladder disease: formation of gallstones or biliary sludge. - Pancreatitis: inflammation of the pancreas presenting with severe abdominal pain. - Severe allergic reaction: rash, swelling, or anaphylaxis.

Patients receiving Myrelez should be monitored for metabolic and biliary effects. - Glucose monitoring: assess blood sugar regularly, especially in diabetic individuals. - Gallbladder evaluation: perform ultrasound if abdominal pain or gallstone history is present. - Pituitary tumor assessment: monitor tumor size and visual fields during therapy. - Hepatic function: use caution in patients with moderate liver impairment. - Hypersensitivity: discontinue if signs of allergic reaction develop. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide acetate may interact with other agents affecting hormone levels or metabolism. Major Interactions (Avoid): - Octreotide: additive hormonal suppression may increase risk of severe hyperglycemia. - Antidiabetic medications: may require dose adjustment due to lanreotide‑induced hyperglycemia. Moderate Interactions (Monitor Closely): - Ketoconazole: can increase lanreotide plasma concentrations. - Glucocorticoids: may mask adrenal insufficiency symptoms. - Diuretics: may influence electrolyte balance and renal function.